Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Clin Genitourin Cancer. 2016 Mar 12;14(5):432–437. doi: 10.1016/j.clgc.2016.03.011

Table 3.

Response to Treatment With Pazopanib and Paclitaxel (n = 28)

Response n (%)
Complete response 3 (11)
Partial response 12 (43)
Stable disease 11 (39)
Progressive disease 2 (7)
Not evaluable 4 (14)
Response rate (complete plus partial response) 15 (54)